Prosecution Insights
Last updated: April 19, 2026
Application No. 18/450,006

SINGLE-PARTICLE ANALYSIS METHOD, AND SYSTEM FOR PERFORMING SAID ANALYSIS

Final Rejection §102
Filed
Aug 15, 2023
Examiner
PRIEST, AARON A
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
On-Chip Biotechnologies Co. Ltd.
OA Round
2 (Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
87%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
486 granted / 794 resolved
+1.2% vs TC avg
Strong +26% interview lift
Without
With
+26.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
30 currently pending
Career history
824
Total Applications
across all art units

Statute-Specific Performance

§101
7.0%
-33.0% vs TC avg
§103
31.8%
-8.2% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
22.4%
-17.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 794 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims Claims 1-2 are pending and the subject of this FINAL Office Action. Withdrawn Rejection The Anticipation rejection based on TAKEDA (US 8,248,604) is withdrawn because it fails to recite valves or three independent pressure sources. Claim Interpretations During examination, claims receive the broadest reasonable interpretation in light of the specification. MPEP § 2111. Applicants are also reminded that “[a]n essential purpose of patent examination is to fashion claims that are precise, clear, correct, and unambiguous” because “[o]nly in this way can uncertainties of claim scope be removed, as much as possible, during the administrative process.” In re Zletz, 893 F.2d 319, 322 (Fed. Cir. 1989). Finally, the patent drafter is in the best position to resolve the ambiguity in the patent claims, and it is highly desirable that patent examiners demand that applicants do so in appropriate circumstances so that the patent can be amended during prosecution rather than attempting to resolve the ambiguity in litigation. Halliburton Energy Servs., Inc. v. M-I LLC, 514 F.3d 1244, 1255 (Fed. Cir. 2008). Claims 1-2 encompass controlling pressure to maintain flow rates constant (which therefore yields constant flow width). In fact, this is explicitly described in the Specification (pg. 23). This is routine in the art. Claims 1-2 are amended to recite “wherein a sample flow rate is controlled by controlling pressures which are applied to the first reservoir, the second reservoir, and the fourth reservoir, separately.” However, this encompasses valving to control the flow of each reservoir. In other words, if there are three reservoirs, there could be two pressure sources, and valves to allow one or more of the pressure sources to control multiple reservoirs. It is also noted that the actual invention disclosed is a device used to sort cells, which is not claimed. Instead, the claims are directed to a mere flow path cartridge with channels and reservoirs controlled by pressure sources. This encompasses a large amount of prior art, and will likely prevent a finding of allowable subject matter, even if TAKEDA is somehow overcome. Claim Rejections - 35 USC § 102 - Maintained The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by TAKEDA (US 2012/0288920). As to claims 1-2 TAKEDA teaches first path 1/27, second path 2 (right or left), third path 2 (right or left), fourth path 4-1 and fifth path 4-2 (Figs. 2-4), and maintaining pressure in paths 2, 27 and 4-1 and 4-2 so that “[t]he width of the sample liquid after joining is about one-tenth of the width of the flow path” (para. 0100). The paths and reservoirs/tanks of TAKEDA are used for identical purpose as that claimed (e.g. sheath liquid surrounds sample liquid in flow channel, Figs. 1-3). A discharge reservoir 11 and 5 is also included (Fig. 4). Response to Arguments Applicants’ arguments do not convince the Examiner that He erred because, first, examples from the specification will not be imported into the claims that do not explicitly do so; second, the claim breadth encompasses valve configurations of the cited prior art; finally, TAKEDA teaches a third pressure source for sample reservoir. Applicants argue that the claimed invention requires the different pressures being separately applied to the first reservoir, the second reservoir, and the fourth reservoir respectively, as shown in the below annotated FIGS. 2(A) and (E). More specifically, the first reservoir (11) is air-pressed by the hallow needle (30), the second reservoir (12) is air-pressed by the hallow needle (31), and the fourth reservoir (21) is air-pressed by the hallow needle (34) (Reply, pg. 5). However, the claims do not require the first reservoir (11) is air-pressed by the hallow needle (30), the second reservoir (12) is air-pressed by the hallow needle (31), and the fourth reservoir (21) is air-pressed by the hallow needle (34). As explained above, all that is required is “a sample flow rate is controlled by controlling pressures which are applied to the first reservoir, the second reservoir, and the fourth reservoir, separately.” To this end, Takeda teach valves to control pressures in each reservoir (e.g. paras. 0025-27). Regardless, TAKEDA (US20120288920) teaches As shown in FIG. 4, a predetermined air pressure may apply to the inside of the reservoir 20 positioned at the upstream end of the chip by a constant-pressure pump which is not shown in FIG. 4. A sample reservoir 10 is formed in the reservoir 20, and the sample liquid is poured into the sample reservoir and the sheath liquid is poured into the outside of the sample reservoir. Phosphate buffer saline (PBS) is preferably used as the sheath liquid. The air pressure common to the sample reservoir and the reservoir 20, causes the sample liquid 1 and the sheath liquid 2 to the right and left of the sample liquid to flow downstream. The three flow paths are joined and the sample liquid flows thinly in the joining flow path 27 while surrounded by the sheath liquids. The width of the flow path 27 is 80 μm and a depth thereof is 50 μm. The width of the sample liquid after joining is about one-tenth of the width of the flow path. The flow path 27 has the oppositely-branched sorting flow paths 4-1 and 4-2 on sides thereof, and the oppositely-branched sorting flow paths connect with the reservoir 5 (para. 0100). In other words, a third pressure source (other two are 8-1 and 8-2 in Fig. 4) is added in order to provide pressure to the sample reservoir 10/20. This allows independent/individual control of three different reservoirs. Prior Art The following prior art, among many, demonstrates that independent pressure sources for each reservoir, including syringes/pistons were routine in the art: US 20020153047 (“In the case of pressure-based systems, operation of the overall system including a valve module typically involves the application of a negative or positive pressure source that is operably coupled to one of the inlet side or outlet side of the overall system, e.g., reservoir 112 or 114, respectively, in FIG. 1. Pressure control also involves the use of controllable pressure sources (positive and/or negative) operably coupled to the reservoirs in the valve module, e.g., reservoirs 116 and 118, where the pressure source or sources coupled to the inlet and outlet sides of the channel system are independently controllable from each other and/or the pressure sources coupled to the valve module. Examples of systems that include multiple, independently controllable pressure sources are described in, e.g., published International Patent Application No. WO 01/63270, which is incorporated herein by reference in its entirety for all purposes. Typically, such systems employ multiple independent pressure pumps, e.g., syringe pumps that are separately operably coupled to each of the reservoirs at which more active and precise control of pressures is desired, e.g., the valve module reservoirs and at least one of the inlet and/or outlet side reservoirs. Control of flow can be accomplished either by monitoring flow while adjusting relative flow rates until the desired flow profile is achieved, or by predetermining the parameters of the control system and channel network, and operating within those parameters (see, e.g., PCT Application NO WO 01/63270, incorporated above).”). Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AARON PRIEST whose telephone number is (571) 270-1095. The examiner can normally be reached on Monday-Friday 10am-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free] If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AARON A PRIEST/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Aug 15, 2023
Application Filed
Jun 04, 2025
Non-Final Rejection — §102
Dec 05, 2025
Response Filed
Feb 12, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601008
Using Hairpin Formation To Identify DNA and RNA Sequences Having A Target Nucleic Acid Sequence
2y 5m to grant Granted Apr 14, 2026
Patent 12595509
SYNTHETIC NUCLEIC ACID SPIKE-INS
2y 5m to grant Granted Apr 07, 2026
Patent 12590328
TARGETED DEPLETION OF NON-TARGET LIBRARY MOLECULES USING POISON PRIMERS DURING TARGET CAPTURE OF NEXT-GENERATION SEQUENCING LIBRARIES
2y 5m to grant Granted Mar 31, 2026
Patent 12589396
DIGITAL TO BIOLOGICAL CONVERTER
2y 5m to grant Granted Mar 31, 2026
Patent 12590341
BRASSICA GAT EVENT AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND/OR DETECTION THEREOF
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
87%
With Interview (+26.0%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 794 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month